Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10260051 Phage therapy of

Patent 10260051 was granted and assigned to Pherecydes Pharma on April, 2019 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

Pherecydes Pharma

0

Current Assignee

Pherecydes Pharma

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Flavie Pouillot0

Helene Blois0

Date of Patent

April 16, 2019

0

Patent Application Number

161310750

Date Filed

September 14, 2018

0

Patent Citations Received

US Patent 11779617 Phage therapy

US Patent 11690885 Anti-bacterial compositions and uses thereof

0

Patent Primary Examiner

Barry A Chestnut

0

Patent abstract

The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Pseudomonas aeruginosa strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10260051 Phage therapy of

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.